4.3 Article Proceedings Paper

Modulation of CD8+ T-cell activation events by monocytic and granulocytic myeloid-derived suppressor cells

期刊

IMMUNOBIOLOGY
卷 218, 期 11, 页码 1385-1391

出版社

ELSEVIER GMBH
DOI: 10.1016/j.imbio.2013.07.003

关键词

Myeloid-derived suppressor cells; TCR signaling; Arginase; iNOS; Reactive oxygen species; Nitric oxide; L-Arginine depletion

向作者/读者索取更多资源

Myeloid-derived suppressor cells are immature myeloid cells, consisting of a monocytic and a granulocytic fraction, that are known to suppress anti-tumor immune responses. Important targets of the immunosuppressive capacity of MDSC are CD8(+) T cells, which are crucial cytotoxic effector cells in immunotherapeutic settings. CD8(+) T-cell activation and differentiation comprises a well-orchestrated series of events, starting from early TCR-mediated signaling and leading to cytokine secretion, the expression of activation markers, proliferation and the differentiation into several subsets of effector and memory cells. In this review, we summarize the available data on how the production of reactive oxygen species, nitric oxide, the arginase-mediated depletion of L-arginine and Cystine depletion by MDSCs interfere with the signaling molecules necessary for normal CTL differentiation and activation. (C) 2013 Elsevier GmbH. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Pharmacology & Pharmacy

Imaging and therapeutic targeting of the tumor immune microenvironment with biologics

Sana Arnouk, Timo W. M. De Groof, Jo A. Van Ginderachter

Summary: The presence and activity of tumor-infiltrating immune cells, such as activated CD8+ T cells and macrophages, play a crucial role in tumor progression and therapy response. Understanding the immune infiltrate in tumors is important for predicting prognosis, optimizing therapeutic success, and monitoring treatment outcomes.

ADVANCED DRUG DELIVERY REVIEWS (2022)

Article Biochemical Research Methods

Single-cell RNA and protein profiling of immune cells from the mouse brain and its border tissues

Isabelle Scheyltjens, Hannah Van Hove, Karen De Vlaminck, Daliya Kancheva, Jonathan Bastos, Monica Vara-Perez, Ana Rita Pombo Antunes, Liesbet Martens, Charlotte L. Scott, Jo A. Van Ginderachter, Yvan Saeys, Martin Guilliams, Niels Vandamme, Kiavash Movahedi

Summary: This protocol provides a detailed workflow for single-cell multi-omic analysis of the mouse brain immune compartment. It includes steps for brain dissection, cell dissociation, high-dimensional flow cytometry, droplet-based single-cell RNA sequencing, and analysis of the data. This optimized workflow allows for a comprehensive assessment of immune cell heterogeneity and activation in the brain, which is crucial for studying neurological disorders.

NATURE PROTOCOLS (2022)

Editorial Material Oncology

The Heat Is On: 20-HETE Instructs an Immunosuppressive Phenotype in Cancer-Associated Fibroblasts

Jo A. Van Ginderachter

Summary: This study uncovers a novel immunosuppressive pathway in non-small cell lung carcinoma, which could enhance the efficacy of immunotherapies by controlling the production of 20-hydroxyeicosatetraenoic acid in cancer cells and modulating the tumor microenvironment. It proposes innovative therapeutic approaches to improve existing immunotherapies.

CANCER RESEARCH (2022)

Article Immunology

Differential plasticity and fate of brain-resident and recruited macrophages during the onset and resolution of neuroinflammation

Karen De Vlaminck, Hannah Van Hove, Daliya Kancheva, Isabelle Scheyltjens, Ana Rita Pombo Antunes, Jonathan Bastos, Monica Vara-Perez, Leen Ali, Myrthe Mampay, Lauren Deneyer, Juliana Fabiani Miranda, Ruiyao Cai, Luc Bouwens, Dimitri De Bundel, Guy Caljon, Benoit Stijlemans, Ann Massie, Jo A. Van Ginderachter, Roosmarijn E. Vandenbroucke, Kiavash Movahedi

Summary: By examining the fate of microglia, border-associated macrophages (BAMs), and recruited macrophages during neuroinflammation and resolution, it was found that their responses and dynamics differ.

IMMUNITY (2022)

Article Immunology

Enteric glial cells favor accumulation of anti-inflammatory macrophages during the resolution of muscularis inflammation

Michelle Stakenborg, Saeed Abdurahiman, Veronica De Simone, Gera Goverse, Nathalie Stakenborg, Lies van Baarle, Qin Wu, Dimitri Pirottin, Jung-Seok Kim, Louise Chappell-Maor, Isabel Pintelon, Sofie Thys, Emilie Pollenus, Louis Boon, Philippe Van den Steen, Marlene Hao, Jo A. Van Ginderachter, Guy E. Boeckxstaens, Jean-Pierre Timmermans, Steffen Jung, Thomas Marichal, Sales Ibiza, Gianluca Matteoli

Summary: Monocyte-derived macrophages (M phi s) play crucial roles in regulating muscularis inflammation. This study investigates the heterogeneity of M phi s at different stages of muscularis inflammation and identifies environmental cues that attract and activate tissue-protective M phi s. Results reveal the presence of two main pro-resolving M phi subpopulations during the resolution of muscularis inflammation, and the activation of EGCs in response to micro-environmental damage is shown to stimulate monocyte infiltration and the subsequent differentiation into anti-inflammatory M phi s. Additionally, CSF1-CSF1R signaling is essential for monocyte differentiation and EGC proliferation during muscularis inflammation.

MUCOSAL IMMUNOLOGY (2022)

Article Oncology

GBM tumors are heterogeneous in their fatty acid metabolism and modulating fatty acid metabolism sensitizes cancer cells derived from recurring GBM tumors to temozolomide

Sweta Parik, Juan Fernandez-Garcia, Francesca Lodi, Karen De Vlaminck, Marleen Derweduwe, Steven De Vleeschouwer, Raf Sciot, Wietse Geens, Linqian Weng, Francesca Maria Bosisio, Gabriele Bergers, Johnny Duerinck, Frederick De Smet, Diether Lambrechts, Jo A. Van Ginderachter, Sarah-Maria Fendt

Summary: This study reveals that the chemotherapeutic agent temozolomide affects fatty acid synthesis and desaturation in newly diagnosed glioblastoma, but this response is blunted in recurring glioblastoma. Furthermore, disrupting cellular fatty acid homeostasis and accumulating saturated fatty acids synergizes with temozolomide treatment, enhancing its efficacy.

FRONTIERS IN ONCOLOGY (2022)

Article Medicine, Research & Experimental

Size-advantage of monovalent nanobodies against the macrophage mannose receptor for deep tumor penetration and tumor-associated macrophage targeting

Marco Erreni, Francesca D'Autilia, Roberta Avigni, Evangelia Bolli, Sana M. Arnouk, Kiavash Movahedi, Pieterjan Debie, Achille Anselmo, Raffaella Parente, Cecile Vincke, Fijs W. B. van Leeuwen, Paola Allavena, Cecilia Garlanda, Alberto Mantovani, Andrea Doni, Sophie Hernot, Jo A. Van Ginderachter

Summary: Nanobodies (Nbs) have been identified as an elegant alternative to conventional monoclonal antibodies for cancer therapy, but there is a lack of detailed microscopic insight into the in vivo pharmacokinetics of different Nb formats in tumor-bearers, especially for the targeting of pro-tumoral tumor-associated macrophages (TAMs) located in less penetrable tumor regions.

THERANOSTICS (2023)

Article Immunology

Junctional adhesion molecule-A is dispensable for myeloid cell recruitment and diversification in the tumor microenvironment

Mate Kiss, Els Lebegge, Aleksandar Murgaski, Helena Van Damme, Daliya Kancheva, Jan Brughmans, Isabelle Scheyltjens, Ali Talebi, Robin Maximilian Awad, Yvon Elkrim, Pauline M. R. Bardet, Sana M. Arnouk, Cleo Goyvaerts, Johan Swinnen, Frank Aboubakar Nana, Jo A. Van Ginderachter, Damya Laoui

Summary: This study found that cancer-associated inflammation can enhance the expression of JAM-A on circulating monocytes, but the function of JAM-A in tumor-infiltrating myeloid cells is little understood. Through gene knockout mouse experiments and RNA sequencing, we found that JAM-A is dispensable for the recruitment and transcriptional reprogramming of myeloid cells.

FRONTIERS IN IMMUNOLOGY (2022)

Review Oncology

Hallmarks of Cancer Affected by the MIF Cytokine Family

Romina Mora Barthelmess, Benoit Stijlemans, Jo A. Van Ginderachter

Summary: The aim of this review is to summarize the available information regarding the MIF family in cancer. MIF and DDT are both highly expressed in cancer patients and their functions are related to 9 out of 10 hallmarks of cancer, indicating their potential as therapeutic targets. New diagnostic methods and treatments have decreased the mortality rates of cancer patients, but further improvements are warranted based on the identification of novel tumor-promoting molecules.

CANCERS (2023)

Review Immunology

A few good reasons to use nanobodies for cancer treatment

Neema Ahishakiye Jumapili, Maida Zivalj, Romina Mora Barthelmess, Geert Raes, Timo W. M. De Groof, Nick Devoogdt, Benoit Stijlemans, Cecile Vincke, Jo A. Van Ginderachter

Summary: mAbs have limitations in their distribution and penetration in tumor microenvironment, as well as their ability to reach the brain. Nanobodies, being smaller in size, possess superior abilities in tumor penetration and infiltration into brain tumors. However, the rapid clearance of nanobodies from circulation may affect their suitability for therapy, although their noncovalent binding to albumin can help increase their serum half-life.

EUROPEAN JOURNAL OF IMMUNOLOGY (2023)

Review Pharmacology & Pharmacy

Current status and future expectations of nanobodies in oncology trials

Tessa De Pauw, Lynn De Mey, Jens M. Debacker, Geert Raes, Jo A. Van Ginderachter, Timo W. M. De Groof, Nick Devoogdt

Summary: Monoclonal antibodies have played a significant role in personalized medicine for cancer, but their size and complexity may hinder certain cancer diagnosis and therapy applications. Nanobodies, with their unique structure and pharmacological features, have shown promising potential as complementary tools for cancer diagnostics and therapeutics. This overview provides insights into nanobody-based diagnostics and therapeutics that have been tested in clinical trials and highlights upcoming preclinical developments.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2023)

Article Radiology, Nuclear Medicine & Medical Imaging

Phase I Study of [68Ga]Ga-Anti-CD206-sdAb for PET/CT Assessment of Protumorigenic Macrophage Presence in Solid Tumors (MMR Phase I)

Odrade Gondry, Catarina Xavier, Laurens Raes, Johannes Heemskerk, Nick Devoogdt, Hendrik Everaert, Karine Breckpot, Quentin Lecocq, Lore Decoster, Christel Fontaine, Denis Schallier, Sandrine Aspeslagh, Ilse Vaneycken, Geert Raes, Jo A. Van Ginderachter, Tony Lahoutte, Vicky Caveliers, Marleen Keyaerts

Summary: Macrophages play a vital role in the body, and anti-inflammatory macrophages targeting CD206 are involved in various diseases. This study evaluated the safety and biodistribution of a PET tracer targeting CD206 in human subjects, and found that the tracer was safe, rapidly cleared from the blood, and enabled high contrast imaging at 90 minutes after injection. Preliminary results showed higher tumor uptake in patients with disease progression.

JOURNAL OF NUCLEAR MEDICINE (2023)

Article Immunology

Flt3L therapy increases the abundance of Treg-promoting CCR7(+) cDCs in preclinical cancer models

Emile J. Clappaert, Daliya Kancheva, Jan Brughmans, Ayla Debraekeleer, Pauline M. R. Bardet, Yvon Elkrim, Dagmar Lacroix, Maida Zivalj, Ahmed E. I. Hamouda, Jo A. Van Ginderachter, Sofie Deschoemaeker, Damya Laoui

Summary: This study found that while Flt3L treatment can increase all cDC subsets in the tumor, it does not reduce tumor growth in any of the models. In addition, in some cases, Flt3L treatment also leads to an increase in CD81(+)migcDC1 subset, which has Treg-inducing potential. Overall, increasing cDC numbers in the tumor alone may not improve anti-tumor responses and may not be beneficial for cancer treatment.

FRONTIERS IN IMMUNOLOGY (2023)

Review Oncology

Lipocalin-2: A Nurturer of Tumor Progression and a Novel Candidate for Targeted Cancer Therapy

Maida Zivalj, Jo A. Van Ginderachter, Benoit Stijlemans

Summary: The aim of this review is to summarize the available information regarding Lipocalin-2 in tumor progression. Lipocalin-2 expression is correlated with tumorigenesis and can be considered as a biomarker and potential drug target in cancer therapy.

CANCERS (2023)

Article Pharmacology & Pharmacy

Self-Immolative Nanobody-Cysteine Residue Modification for Controlled Immunodrug Delivery

Maximilian Scherger, Yannick A. A. Pilger, Judith Stickdorn, Patric Komforth, Sascha Schmitt, Sana M. M. Arnouk, Els Lebegge, Kaloian Koynov, Hans-Joachim Rader, Jo A. A. Van Ginderachter, Lutz Nuhn

Summary: In this study, a procedure is demonstrated for site-specific reversible bioconjugation of genetically engineered single domain antibodies, called nanobodies, using self-immolative linkers (SILs). The flow cytometry and microscopy images confirm cellular uptake and biological affinity of the modified nanobodies. This strategy can be extended to other therapeutically relevant representatives of nanobodies, highlighting the versatility of this reversible reductive-responsive bioconjugation in a broad field of applications.

ADVANCED THERAPEUTICS (2023)

暂无数据